/ FULC
Why Fulcrum Therapeutics Stock Is Surging Nearly 50% Today?
Fulcrum Therapeutics rose nearly 50% premarket after positive Phase 1b trial results for its sickle cell drug, showing strong efficacy signals and a favorable ...
December 08, 2025Fulcrum Therapeutics rose nearly 50% premarket after positive Phase 1b trial results for its sickle cell drug, showing strong efficacy signals and a favorable ...
December 08, 2025